BR112015023233A8 - conjugados de hemoglobina, composição farmacêutica e uso de um conjugado de hemoglobina - Google Patents
conjugados de hemoglobina, composição farmacêutica e uso de um conjugado de hemoglobina Download PDFInfo
- Publication number
- BR112015023233A8 BR112015023233A8 BR112015023233A BR112015023233A BR112015023233A8 BR 112015023233 A8 BR112015023233 A8 BR 112015023233A8 BR 112015023233 A BR112015023233 A BR 112015023233A BR 112015023233 A BR112015023233 A BR 112015023233A BR 112015023233 A8 BR112015023233 A8 BR 112015023233A8
- Authority
- BR
- Brazil
- Prior art keywords
- hemoglobin
- pharmaceutical composition
- conjugates
- conjugate
- polyethylene glycol
- Prior art date
Links
- 102000001554 Hemoglobins Human genes 0.000 title abstract 5
- 108010054147 Hemoglobins Proteins 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- DRLIANXPAARUMI-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) pentanoate Chemical compound CCCCC(=O)ON1C(=O)CCC1=O DRLIANXPAARUMI-UHFFFAOYSA-N 0.000 abstract 1
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 150000003141 primary amines Chemical class 0.000 abstract 1
- 235000014393 valine Nutrition 0.000 abstract 1
- 150000003680 valines Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361801016P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/030569 WO2014145755A1 (en) | 2013-03-15 | 2014-03-17 | Polyalkylene oxide valerate hemoglobin conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015023233A2 BR112015023233A2 (pt) | 2017-07-18 |
| BR112015023233A8 true BR112015023233A8 (pt) | 2019-12-03 |
Family
ID=51538084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015023233A BR112015023233A8 (pt) | 2013-03-15 | 2014-03-17 | conjugados de hemoglobina, composição farmacêutica e uso de um conjugado de hemoglobina |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10821158B2 (https=) |
| EP (1) | EP2968597B1 (https=) |
| JP (1) | JP6657070B2 (https=) |
| KR (1) | KR102238718B1 (https=) |
| CN (1) | CN105188761B (https=) |
| AU (1) | AU2014232540B2 (https=) |
| BR (1) | BR112015023233A8 (https=) |
| CA (1) | CA2906878C (https=) |
| MX (1) | MX373193B (https=) |
| WO (1) | WO2014145755A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10506829B2 (en) | 2016-02-26 | 2019-12-17 | Freelander Innovations USA, LLC | System and method for a vaporizer |
| CA3070172A1 (en) | 2017-07-18 | 2019-01-24 | VirTech Bio, Inc. | Blood substitutes comprising hemoglobin and methods of making |
| GB201721503D0 (en) * | 2017-12-20 | 2018-01-31 | Univ Essex | Modified globin proteins |
| WO2021037109A1 (en) * | 2019-08-29 | 2021-03-04 | Billion King International Ltd. | Thiosuccinyl-crosslinked hemoglobin analogs and methods of use and preparation thereof |
| US11535655B2 (en) * | 2019-12-06 | 2022-12-27 | Cheer Global Limited | Method of treating inflammatory bowel disease |
| WO2022184005A1 (en) | 2021-03-01 | 2022-09-09 | Billion King International Limited | Thiosuccinyl-crosslinked hemoglobin conjugates and methods of use and preparation thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4529719A (en) | 1983-05-04 | 1985-07-16 | Tye Ross W | Modified crosslinked stroma-free tetrameric hemoglobin |
| EP0206448B1 (en) * | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| CA1312009C (en) | 1986-11-10 | 1992-12-29 | Carl W. Rausch | Extra pure semi-synthetic blood substitute |
| GB8710598D0 (en) | 1987-05-05 | 1987-06-10 | Star Medical Diagnostics Ltd | Hemoglobin based blood substitute |
| US5234903A (en) | 1989-11-22 | 1993-08-10 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute |
| US5650388A (en) | 1989-11-22 | 1997-07-22 | Enzon, Inc. | Fractionated polyalkylene oxide-conjugated hemoglobin solutions |
| US5250665A (en) | 1991-05-31 | 1993-10-05 | The University Of Toronto Innovations Foundation | Specifically β-β cross-linked hemoglobins and method of preparation |
| ATE302019T1 (de) * | 1997-02-28 | 2005-09-15 | Univ California | Verfahren und zusammensetzungen zur optimierung des sauerstofftransportes in zellfreien systemen |
| KR100316154B1 (ko) | 1999-03-26 | 2001-12-12 | 노광 | 폴리에틸렌글리콜－헤모글로빈 결합체 |
| DE10031744A1 (de) | 2000-06-29 | 2002-01-17 | Sanguibio Tech Ag | Mit Blutplasma verträgliche, vernetzte und mit Polyalkylenoxiden konjugierte Säugetierhämoglobine als künstliche medizinische Sauerstoffträger, ihre Herstellung und ihre Verwendung |
| DE10031740A1 (de) | 2000-06-29 | 2002-02-14 | Sanguibio Tech Ag | Künstliche Sauerstoffträger aus vernetztem modifizierten Human- oder Schweinehämoglobin mit verbesserten Eigenschaften, Verfahren zu ihrer technisch einfachen Herstellung aus gereinigtem Material in hohen Ausbeuten, sowie deren Verwendung |
| US20030153491A1 (en) | 2002-01-11 | 2003-08-14 | Winslow Robert M. | Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
| DE10220992A1 (de) | 2002-05-11 | 2003-12-04 | Sanguibiotech Ag | Verwendung eines oder mehrerer Sauerstoffträger, ausgewählt aus Hämoglobin, Myoglobin und Derivaten hiervon zur Behandlung einer Organfunktionsstörung infolge eines akuten Versorgungsmangels und zur Behandlung/Vermeidung einer Gewebeschädigung infolge einer solchen Störung |
| MXPA05000796A (es) | 2002-07-24 | 2005-04-19 | Hoffmann La Roche | Aditivos de acidos polialquilenglicolicos. |
| US20040072729A1 (en) | 2002-10-10 | 2004-04-15 | Sunbio Inc. | High oxygen affinity PEG-hemoglobin as treatment for brain stroke |
| CA2511494A1 (en) | 2002-12-23 | 2004-07-15 | Seetharama A. Acharya | Non-hypertensive polyethylene glycol-modified hemoglobin as oxygen carrier |
| KR100512483B1 (ko) | 2003-05-07 | 2005-09-05 | 선바이오(주) | 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법 |
| DE10352692A1 (de) | 2003-11-12 | 2005-06-23 | Sanguibiotech Gmbh | Verwendung hypo-onkotischer Lösungen in das Blut addierbarer, hyperpolymerer Hämoglobine zur Behandlung eines Lungenödems |
| WO2006096774A2 (en) | 2005-03-07 | 2006-09-14 | Sangart, Inc. | Composition and methods for delivering carbon monoxide (co) and nitric ozide (no) co to tissue using heme proteins as carriers |
| NO2440239T3 (https=) * | 2009-06-09 | 2018-02-10 | ||
| JP2015514718A (ja) | 2012-04-03 | 2015-05-21 | サンガート， インコーポレイテッド | スクシンイミド活性化されたニトロキシル化合物およびタンパク質のニトロキシル化のためのその使用のための方法 |
-
2014
- 2014-03-17 JP JP2016503422A patent/JP6657070B2/ja active Active
- 2014-03-17 BR BR112015023233A patent/BR112015023233A8/pt not_active Application Discontinuation
- 2014-03-17 CN CN201480015028.0A patent/CN105188761B/zh active Active
- 2014-03-17 MX MX2015013263A patent/MX373193B/es active IP Right Grant
- 2014-03-17 AU AU2014232540A patent/AU2014232540B2/en active Active
- 2014-03-17 CA CA2906878A patent/CA2906878C/en active Active
- 2014-03-17 WO PCT/US2014/030569 patent/WO2014145755A1/en not_active Ceased
- 2014-03-17 EP EP14765388.5A patent/EP2968597B1/en active Active
- 2014-03-17 US US14/777,261 patent/US10821158B2/en active Active
- 2014-03-17 KR KR1020157027637A patent/KR102238718B1/ko active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102238718B1 (ko) | 2021-04-12 |
| JP2016521258A (ja) | 2016-07-21 |
| HK1219053A1 (zh) | 2017-03-24 |
| AU2014232540B2 (en) | 2018-09-20 |
| EP2968597A1 (en) | 2016-01-20 |
| KR20150132235A (ko) | 2015-11-25 |
| EP2968597A4 (en) | 2016-11-02 |
| MX373193B (es) | 2020-05-07 |
| EP2968597B1 (en) | 2021-08-18 |
| US10821158B2 (en) | 2020-11-03 |
| CN105188761B (zh) | 2020-05-15 |
| BR112015023233A2 (pt) | 2017-07-18 |
| US20160022783A1 (en) | 2016-01-28 |
| AU2014232540A1 (en) | 2015-10-29 |
| JP6657070B2 (ja) | 2020-03-04 |
| CN105188761A (zh) | 2015-12-23 |
| WO2014145755A1 (en) | 2014-09-18 |
| CA2906878C (en) | 2021-09-21 |
| CA2906878A1 (en) | 2014-09-18 |
| MX2015013263A (es) | 2015-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201690744A1 (ru) | Конъюгаты белок-полимер-лекарственное средство | |
| MX2024002632A (es) | Enlazadores que contienen peptido para conjugados anticuerpo-farmaco. | |
| MX2019000566A (es) | Suministro mediado por ve de conjugados de proteína de enlace-molécula pequeña. | |
| ZA201903667B (en) | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers | |
| BR112015023233A8 (pt) | conjugados de hemoglobina, composição farmacêutica e uso de um conjugado de hemoglobina | |
| MX2020001212A (es) | Conjugados anticuerpo-farmaco a base de antraciclina que tienen alta tolerabilidad in vivo. | |
| MX2023001582A (es) | Conjugados proteina-polimero-farmaco. | |
| BR112016017893A2 (pt) | conjugado de anticorpo-fármaco anti-her3 | |
| PH12014501924A1 (en) | Xten conjugate compositions and methods of making same | |
| TR201900176T4 (tr) | Anti-TROP2 antikor-ilaç konjugatı. | |
| ZA201805336B (en) | Amanitin conjugates | |
| CY1122483T1 (el) | Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης | |
| MX2016007865A (es) | Peptidos citotoxicos y conjugados de los mismos. | |
| MX385823B (es) | Conjugados de anticuerpo-farmaco hidrofilicos. | |
| MX2017013154A (es) | Conjugados anticuerpo-farmaco de sitio especifico. | |
| EP4372002A3 (en) | Proximity-based sortase-mediated protein purification and ligation | |
| MX2017005199A (es) | Conjugados y reactivos de conjugacion. | |
| BR112015032200A2 (pt) | conjugado anticorpo-droga com estabilidade melhorada, método de preparação, composição farmacêutica e uso do mesmo | |
| EA202191175A1 (ru) | Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры | |
| EA202090319A1 (ru) | Пептидные конъюгаты, способ конъюгации и их использование | |
| AR092897A1 (es) | Composiciones inmunogenicas | |
| MX2017013171A (es) | Conjugados anticuerpo-farmaco de sitio especifico. | |
| NZ762865A (en) | Psma-targeting amanitin conjugates | |
| CL2018000131A1 (es) | Inmunoconjugados de il22 | |
| ZA202101990B (en) | Sulfomaleimide-based linkers and corresponding conjugates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/00 (2006.01), A61K 38/42 (2006.01), C07K 1 |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |